Company Overview - CENTOGENE is a biodata life science partner focused on rare and neurodegenerative diseases[1] - The company possesses a large real-world data repository for rare and neurodegenerative diseases and offers a broad diagnostic testing portfolio[6] - CENTOGENE aims to accelerate and de-risk drug discovery to market access[6] Market Opportunity - By 2024, 18% of prescription sales worldwide are expected to target rare diseases[7] - Approximately 350 million people are affected by rare genetic diseases, with about 90% remaining undiagnosed[7] - The rare diseases market is expected to grow at a rate of 11+% by 2024[7] - Over 50% of FDA approvals in 2021 were orphan drugs[7] Strategy and Growth - The company is focused on a unique and transformative business model and expanding pharma partnerships, targeting ~20+ new pipeline deals[19] - CENTOGENE aims to continue growing diagnostics at an above-market level, focusing on profitable growth, commercial excellence, CentoCloud & multiomics[19] - The company is managing costs by driving a fit-for-purpose organization and focusing on efficient operations and margin improvement[19] Financial Performance - The company's 2022 revenue guidance is +15-20% year-over-year, with revenues of approximately €50-52 million[19] - In 2022, the company had €10.3 million up +3% year-over-year acceleration in 2H22 driven by biopharma[20] - In Q1 2022, CENTOGENE secured $62 million (~€55 million) in financing, including a €15 million PIPE and a $45 million secured debt facility[20]
Centogene (CNTG) presents at H.C. Wainwright 24th Annual Global Investment Conference - Slideshow